Neptune Technologies & Bioressources Inc. announces positive preliminary clinical results and the deposit of an international patent demand for some applications of its krill oil NKO™

MONTREAL, June 26 , 2002

Neptune Technologies & Bioressources Inc. TSX-V (NTB) announces positive preliminary clinical results as well as an international patent demand for certain applications of its Neptune Krill Oil™ (NKO™).

The analysis of the preliminary pilot study results showed a significant reduction (15%) of blood cholesterol among patients who took a daily dose of krill oil NKO™, without changing their eating habits during a two month period. Several female patients suffering from premenstrual syndrome symptoms, as well as patients with arthritis reported significant improvement of their symptoms.

After filing for seven patents in the U.S.A., June 18th, 2001, Neptune is reaching another milestone with an international patent demand for one of its application patents. The international patent demand, logical result of Neptune recommended strategy, aims to reinforce its intellectual property protection which covers the following applications : cardiovascular disease, hyperglycaemia, premenstrual syndrome, skin cancer, facial wrinkles and transdermal transport. This request will lead Neptune to finalize the protection of its applications in many countries including Canada, U.S.A. as well as some countries of South America, Europe and Asia. With this achievement, Neptune aims to obtain the recognition of the unique content and the superior efficiency of NKO™ on certain human conditions.

Dr. Tina Sampalis, Vice-President of Research at Neptune Technologies & Bioressources Inc. says : “Neptune has invested and continues to invest in human and financial resources in order to produce and validate krill oil NKO™ as a unique product with several beneficial properties for certain human conditions. Favourable preliminary results allow us to move ahead towards an international patent demand which will open new horizons of possibilities for Neptune. These results confirm the orientation of our clinical research studies to be conducted to confirm the validation of our hypotheses on the benefits of our krill oil NKO™ in order to meet the expectation of our potential clients.”

Neptune Technologies & Bioressources Inc. exploits extraction processes for marine biomasses such as krill and other underexploited marine resources such as red crab and calanus, in order to offer its products to the nutraceutical, cosmetic, cosmeceutical and biopharmaceutical markets.

Due to its technologies, Neptune Technologies & Bioressources Inc. is strategically well positioned in the huge and emerging health and wellness markets in which natural biomass extraction will play an important role in developing nutrigenomics, the next wave in nutritional research.

Neptune Technologies & Bioressources Inc. is listed on the TSX Venture Exchange where its shares trade under the ticker symbol NTB.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this news release.

For additional information:
Renmark Financial Communication Inc.
Sylvain Laberge : [email protected]
Pierre Dewolf : [email protected]
Tel. : (514) 939-3989
Fax : (514) 939-3717

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.